Prostate cancer trials in Spain

In Spain 102 Also abroad 1481

102 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Where
Barcelona, Granada, L'hospitalet De Llobregat, Madrid, Murcia, Sevilla, Valencia
Age
18 years to 100 years
People
450 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT05939414 · EU 2022-502956-29-00
Phase 3Taking people
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Where
A Coruña, Barcelona, Burgos, Girona, Las Palmas de Gran Canaria, Málaga, Pozuelo de Alarcón, Sabadell
Age
18 years and over
People
1,314 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136650 · EU 2023-504957-11-00
Phase 3Taking people
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Where
A Coruña, Barcelona, L'Hospitalet de Llobregat, Lugo, Madrid, Majadahonda, Málaga, Pamplona
Age
18 years and over
People
750 worldwide
Run by
Amgen
See details and how to joinNCT07213674
No phaseTaking people
A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
Where
Many Locations
Age
18 years and over
People
1,600 worldwide
Run by
Bayer
See details and how to joinNCT07344779
Phase 3Taking people
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Santiago de Compostela
Age
18 years and over
People
670 worldwide
Run by
AstraZeneca
See details and how to joinNCT07611110
Phase 3Taking people
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Valencia
Age
18 years and over
People
736 worldwide
Run by
BioNTech SE
See details and how to joinNCT07365995 · EU 2025-524445-27-00
Phase 1Taking people
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Where
Barcelona, Castello De La Plana, L'Hospitalet de Llobregat, Madrid, Málaga, Pozuelo de Alarcón, Valencia
Age
18 years and over
People
453 worldwide
Run by
Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00
Phase 1/2Taking people
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Where
Barcelona, Granada, L'Hospitalet de Llobregat, Madrid
Age
18 years and over
People
123 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07226986 · EU 2025-521859-23-00
Phase 3Taking people
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
Where
Barcelona, Córdoba, Las Palmas de Gran Canaria, Madrid, Santander, Valencia
Age
18 years and over
People
1,330 worldwide
Run by
AstraZeneca
See details and how to joinNCT07711002 · EU 2026-526275-38-00
Phase 3Taking people
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Where
Barcelona, Girona, Madrid, Majadahonda, Málaga, Oviedo, Sabadell, Santander, Valencia
Age
18 years and over
People
700 worldwide
Run by
AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00
Phase 3Taking people
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Where
Barcelona, Madrid, Málaga, Manresa, Valencia, Vigo
Age
18 years and over
People
1,000 worldwide
Run by
Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00
Phase 1/2Taking people
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona
Age
18 years to 99 years
People
152 worldwide
Run by
AstraZeneca
See details and how to joinNCT07590934
Phase 1Not yet taking people in Spain
ITR-251 in Patients With Advanced Solid Tumors
Where
L'Hospitalet de Llobregat
Age
18 years and over
People
46
Run by
ITERIA BIOPHARMA, S.L.
See details and how to joinNCT07870096 · EU 2026-527383-32-00
Phase 1/2Taking people
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Where
L'Hospitalet de Llobregat, Madrid, Sevilla
Age
18 years and over
People
360 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06863272 · EU 2024-516036-94-00
Phase 1/2Taking people
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Where
L'Hospitalet de Llobregat, Madrid, Santiago de Compostela
Age
18 years and over
People
188 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07206056 · EU 2025-521880-10-00
No phaseTaking people
Study on Prostate Salvage Using High-dose-rate Brachytherapy
Where
Barakaldo, Benidorm, Córdoba, L'Hospitalet de Llobregat, Madrid, Pamplona, San Sebastián, Santander, Valencia, Vigo
Age
18 years and over
People
63
Run by
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
See details and how to joinNCT07860528
Phase 1/2Taking people
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Where
A Coruña, Barcelona, Málaga, Pozuelo de Alarcón, Sant Cugat del Vallès, Sevilla
Age
18 years to 130 years
People
695 worldwide
Run by
AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00
Phase 2Taking people
Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer
Where
Badalona, Barakaldo, Barcelona, Madrid, Málaga, Sabadell, Santander, Zaragoza
Age
18 years and over
People
78 worldwide
Run by
Fundacion Oncosur
See details and how to joinNCT06582628 · EU 2023-510536-37-00
Phase 1Taking people
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Where
Barcelona, Madrid
Age
18 years and over
People
180 worldwide
Run by
Olema Pharmaceuticals, Inc.
See details and how to joinNCT06784193
Phase 1/2Taking people
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Where
Badajoz, Barcelona, Madrid, Málaga, Pozuelo de AlarcOn Madr
Age
18 years and over
People
85 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06990880 · EU 2025-521581-10-00
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Barcelona, Madrid, Rioja, Valencia
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 1Taking people
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Where
Badajoz, Barcelona, Madrid, Pamplona, Santander, Sevilla, Valencia
Age
18 years and over
People
1,394 worldwide
Run by
Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00
Phase 1/2Taking people
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Where
Barcelona, L'hospitalet De Llobregat, Madrid, Majadahonda
Age
18 years and over
People
181 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07190300 · EU 2025-521873-15-00
Phase 3Taking people
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
Where
Bilbao
Age
50 years to 70 years
People
1,284 worldwide
Run by
University of Alberta
See details and how to joinNCT06626022
Phase 1Taking people
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
Where
Barcelona, Madrid, Málaga
Age
18 years and over
People
83 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07277270 · EU 2025-522274-37-00